News

U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated

Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved INLEXZO™ (gemcitabine ...
News-Medical.Net on MSN7mon

New urine-based kit promises accurate bladder cancer diagnosis at home

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries such as ...